International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
Summary
The study PNET 5 MB has been designed for children with medulloblastoma of standard risk (according to the risk-group definitions which have been used so far; e.g. in PNET 4). With the advent of biological parameters for stratification into clinical medulloblastoma trials, the ß-catenin status will be the only criterion according to which study patients will be assigned to either treatment arm PNET 5 MB - LR or to PNET 5 MB - SR, respectively. The initial diagnostic assessments (imaging, staging, histology, and tumor biology) required for study entry are the same for both treatment arms. With the amendment for version 12 of the protocol, patients who have a WNT-activated medulloblastoma with clinically high-risk features can be included in the PNET 5 MB WNT-HR study, and patients with a high-risk SHH medulloblastoma with TP53 mutation (both somatic or germline including mosaicism) can be included in the PNET5 MB SHH-TP53 study. Data on patients with pathogenic germline alteration or cancer predisposition syndrome, who cannot be included in any prospective trial due to unavailability or due to physician or family decision, can be documented within the observational PNET 5 MB registry.
Timeline
- Start
- 2014-06
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 200 mg/m2 | Other |
| Subject | Cisplatin | Other / unclassified | 70 mg/m2 | — |
| Subject | Cyclophosphamide | Other / unclassified | 1000 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | 37.5 mg/m2 | Other |
| Subject | Lomustine | Small molecule | 75 mg/m2 | — |
| Subject | MTX | Unknown | 2 mg | Other |
| Subject | MTX | Unknown | 5 g | Other |
| Subject | Vinblastin | Unknown | 5 mg/m2 | — |
| Subject | Vincristine | Small molecule | 1.5 mg/m2 | — |
| Background | Leucovorin | Small molecule | — | — |